Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma

Abstract Background Fibroblast growth factor receptor 3 (FGFR3) is up-regulated as a result of the t(4;14)(p16;q32) translocation that occurs in up to 20% of multiple myeloma (MM) patients. Recent studies have demonstrated that up-regulation of FGFR3 promotes cell survival, growth and drug resistanc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2011-09, Vol.35 (9), p.1233-1240
Hauptverfasser:	de Brito, Luis R, Batey, Mike A, Zhao, Yan, Squires, Matt S, Maitland, Helen, Leung, Hing Y, Hall, Andrew G, Jackson, Graham, Newell, David R, Irving, Julie A.E
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - therapeutic use Cell Line, Tumor Drug Evaluation, Preclinical FGFR3 Hematology, Oncology and Palliative Medicine Humans Indoles - therapeutic use Mice Mice, Inbred BALB C Mice, Nude Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Multiple Myeloma - pathology PD173074 Phthalazines - therapeutic use Piperidines - therapeutic use Protein Kinase Inhibitors - therapeutic use Pyridines - therapeutic use Pyrimidines - therapeutic use Pyrroles - therapeutic use Quinazolines - therapeutic use Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Sunitinib Vandetanib Vatalanib Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!